Skip to main content
Premium Trial:

Request an Annual Quote

Percentage Change in Stock Valuation in 6-Month Period Ended March 8, 2005








Harvard Bio’s Weekly Stock Performance Since April 10, 2003.*
9/8/2004
3/8/2005
Pct. Change
Molecular Devices
24.18
20.05
-17.08
Bio-Rad
51.62
48.51
-6.02
Harvard Bio
4.71
4.43
-5.94
Thermo
26.59
27.69
4.14
Strategene
7.09
7.39
4.23
GE
33.66
36.06
7.13
Applied Biosystems
18.83
20.69
9.88
Waters
44.56
49.32
10.68
Sigma
56.51
63.79
12.88
Bruker
3.3
3.78
14.55
BD
50.62
58.85
16.26
Beckman
58.18
69.88
20.11
Agilent
20.18
24.36
20.71
PerkinElmer
17.38
23.01
32.39
Invitrogen
48.87
71.66
46.63
Total
31.09
35.30
13.55

File Attachments
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.